STXS

Stereotaxis, Inc. 2005 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: Stereotaxis, Inc.
Reporting Period: Fiscal year ended December 31, 2005
Business Overview: Stereotaxis designs, manufactures, and markets the Stereotaxis System, an advanced cardiology instrument control system used in hospital catheterization labs ("cath labs"). The system utilizes computer-controlled magnetic fields to remotely navigate catheters and guidewires for the treatment of coronary artery disease and arrhythmias. The company operates through strategic alliances with Siemens, Philips, and Biosense Webster for imaging integration, sales, and service.

Key Financial Metrics

Key Operational Data:

• Systems sold in 2005: 13 (vs. 22 in 2004).
• Total systems installed as of Dec 31, 2005: 43.
• Backlog (purchase orders/commitments): $26 million as of Dec 31, 2005 (vs. $20 million in 2004).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 20% to $15.0 million. System sales revenue dropped 26% due to selling only 13 systems in 2005 compared to 22 in 2004. This was attributed to delays in regulatory approval for certain catheters and slower domestic order rates.
• Expense Increases:
  • General & Administrative (G&A): Increased 91% to $13.2 million, driven by costs associated with public company status (audit, insurance, regulatory compliance) following the 2004 IPO.
  • Sales & Marketing: Increased 52% to $17.4 million due to hiring additional sales personnel and expanded marketing programs.
  • Royalty Settlement: A one-time charge of $2.9 million was recorded in 2005 to resolve a patent licensing dispute with the University of Virginia Patent Foundation.
• Liquidity Position: Cash and short-term investments decreased significantly from $45.6 million to $10.7 million, primarily due to operating losses and a reduction in the investment portfolio. Working capital declined from $50.4 million to $15.9 million.

Guidance, Outlook, and Risks

Outlook: Management expects to incur substantial net losses through the latter part of 2007 as the company scales sales, marketing, and R&D operations. The company anticipates negative cash flow from operations for the foreseeable future.

Recent Capital Activity: In February 2006 (subsequent to the reporting period), the company completed a registered direct offering raising approximately $61.7 million in net proceeds.

Key Risks and Contingencies:

• Market Adoption: Success depends on hospitals purchasing expensive capital equipment and physicians adopting a new technology over established manual methods.
• Regulatory Approvals: Future revenue growth relies on obtaining FDA clearance for additional disposable interventional devices (e.g., HELIOS ablation catheter PMA filed in 2005).
• Collaboration Dependence: The business model relies heavily on alliances with Siemens, Philips, and Biosense Webster for sales, distribution, and product integration.
• Backlog Uncertainty: While $26 million in orders exists, revenue recognition is contingent on installation, which is subject to hospital construction schedules and regulatory approvals.
• Profitability: The company has an accumulated deficit of $158 million and no assurance it will ever achieve profitable operations.

Investor Verification Checklist

• Backlog Conversion: Verify the rate at which the $26 million backlog is converting to recognized revenue, noting the risk of order cancellations or delays.
• Regulatory Status: Confirm the status of the PMA application for the HELIOS ablation catheter and other pending device clearances.
• Cash Burn Rate: Assess the runway provided by the $10.7 million cash balance (as of 2005) plus the $61.7 million raised in Feb 2006 against the projected operating losses through 2007.
• Partnership Health: Monitor the execution and revenue contribution of the strategic alliances with Siemens, Philips, and Biosense Webster.
• Expense Management: Evaluate whether G&A and Sales & Marketing expenses can be stabilized as the company matures post-IPO.